High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis.

[1]  J. Teruya-Feldstein,et al.  Risk‐adapted autologous stem cell transplantation with adjuvant dexamethasone ± thalidomide for systemic light‐chain amyloidosis: results of a phase II trial , 2007, British journal of haematology.

[2]  F. Jardin,et al.  High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. , 2007, The New England journal of medicine.

[3]  P. Hawkins,et al.  Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis. , 2007, Blood.

[4]  G. Merlini,et al.  Dangerous small B-cell clones. , 2006, Blood.

[5]  S. Ansell,et al.  Risk-adjusted manipulation of melphalan dose before stem cell transplantation in patients with amyloidosis is associated with a lower response rate , 2004, Bone Marrow Transplantation.

[6]  R. Falk,et al.  High-Dose Melphalan and Autologous Stem-Cell Transplantation in Patients with AL Amyloidosis: An 8-Year Study , 2004, Annals of Internal Medicine.

[7]  A. Dispenzieri,et al.  Stem cell transplantation for the management of primary systemic amyloidosis. , 2002, The American journal of medicine.

[8]  M. Gertz,et al.  Autologous stem cell transplantation for primary systemic amyloidosis. , 2002, Blood.

[9]  T. Therneau,et al.  Eligibility for hematopoietic stem-cell transplantation for primary systemic amyloidosis is a favorable prognostic factor for survival. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.